OBJECTIVE: Treatment decisions in advanced breast cancer are complex, with enhanced quality of life and survival among important treatment goals. Patients with metastatic breast cancer face the decision of whether or not to have chemotherapy, and many wish to be involved in this decision. We report the development and evaluation of a decision aid (DA) designed to assist patients facing this treatment decision. DESIGN AND SAMPLE: Women with metastatic breast cancer (n = 17)and medical oncologists in Australia and Canada (n = 7) were invited to evaluate the DA. INTERVENTION: A DA was developed for patients with hormone resistant metastatic breast cancer considering chemotherapy. The DA presented options of supportive care, with or without chemotherapy. Potential benefits and side effects of different chemotherapy regimens, and evidence-based prognostic estimates were described,and a values clarification exercise included. MAIN OUTCOME MEASURES: Patient questionnaires evaluating information and decision involvement preferences, attitudes toward the DA and oncologist feedback regarding attitudes toward the DA. RESULTS: Seventeen patients participated; fifteen desired as much information about their illness as possible; sixteen wished to be actively involved in the decision-making process. The majority rated the DA as highly acceptable, clear and informative, and would recommend it to others facing this treatment decision. CONCLUSION: This is the first DA for patients with advanced metastatic breast cancer considering chemotherapy. A randomized trial is underway to evaluate its role in clinical decision-making.
OBJECTIVE: Treatment decisions in advanced breast cancer are complex, with enhanced quality of life and survival among important treatment goals. Patients with metastatic breast cancer face the decision of whether or not to have chemotherapy, and many wish to be involved in this decision. We report the development and evaluation of a decision aid (DA) designed to assist patients facing this treatment decision. DESIGN AND SAMPLE: Women with metastatic breast cancer (n = 17)and medical oncologists in Australia and Canada (n = 7) were invited to evaluate the DA. INTERVENTION: A DA was developed for patients with hormone resistant metastatic breast cancer considering chemotherapy. The DA presented options of supportive care, with or without chemotherapy. Potential benefits and side effects of different chemotherapy regimens, and evidence-based prognostic estimates were described,and a values clarification exercise included. MAIN OUTCOME MEASURES: Patient questionnaires evaluating information and decision involvement preferences, attitudes toward the DA and oncologist feedback regarding attitudes toward the DA. RESULTS: Seventeen patients participated; fifteen desired as much information about their illness as possible; sixteen wished to be actively involved in the decision-making process. The majority rated the DA as highly acceptable, clear and informative, and would recommend it to others facing this treatment decision. CONCLUSION: This is the first DA for patients with advanced metastatic breast cancer considering chemotherapy. A randomized trial is underway to evaluate its role in clinical decision-making.
Authors: S Molenaar; M A Sprangers; E J Rutgers; E J Luiten; J Mulder; P M Bossuyt; J J van Everdingen; P Oosterveld; H C de Haes Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A M O'Connor; P Tugwell; G A Wells; T Elmslie; E Jolly; G Hollingworth; R McPherson; H Bunn; I Graham; E Drake Journal: Patient Educ Couns Date: 1998-03
Authors: Valerie Fiset; Annette M. O'Connor; William Evans; Ian Graham; Catherine Degrasse; Jo Logan Journal: Health Expect Date: 2000-06 Impact factor: 3.377
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Thomas J Smith; Lindsay A Dow; Enid A Virago; James Khatcheressian; Robin Matsuyama; Laurel J Lyckholm Journal: J Support Oncol Date: 2011 Mar-Apr
Authors: Linda J M Oostendorp; Petronella B Ottevanger; A Rogier T Donders; Agnes J van de Wouw; Ivonne J H Schoenaker; Tineke J Smilde; Winette T A van der Graaf; Peep F M Stalmeier Journal: BMC Med Inform Decis Mak Date: 2017-08-31 Impact factor: 2.796